Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma
Technology appraisal guidance
Reference number: TA1113
Published:
Please note that following on from information received from the company this appraisal has been rescheduled to align with latest regulatory expectations and the appraisal is now anticipated to begin in late November 2024.